MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Diane M. Pereira 1 , André E. S. Simões 1 , Sofia E. Gomes 1 , Rui E. Castro 1 , Tânia Carvalho 2 , Cecília M. P. Rodrigues 1, * , Pedro M. Borralho 1, * 1 Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal 2 Histology and Comparative Pathology Laboratory, Instituto de Medicina Molecular, Lisbon, Portugal * These authors have contributed equally and share senior authorship Correspondence to: Cecília M. P. Rodrigues, email: cmprodrigues@ff.ulisboa.pt Pedro M. Borralho, email: borralho@ff.ulisboa.pt Keywords: MEK5/ERK5, p53, 5-fluorouracil, apoptosis, chemosensitization Received: November 16, 2015 Accepted: March 31, 2016 Published: April 29, 2016 ABSTRACT The MEK5/ERK5 signaling pathway is emerging as an important contributor to colon cancer onset, progression and metastasis; however, its relevance to chemotherapy resistance remains unknown. Here, we evaluated the impact of the MEK5/ERK5 cascade in colon cancer cell sensitivity to 5-fluorouracil (5-FU). Increased ERK5 expression was correlated with poor overall survival in colon cancer patients. In colon cancer cells, 5-FU exposure impaired endogenous KRAS/MEK5/ERK5 expression and/or activation. In turn, MEK5 constitutive activation reduced 5-FU-induced cytotoxicity. Using genetic and pharmacological approaches, we showed that ERK5 inhibition increased caspase-3/7 activity and apoptosis following 5-FU exposure. Mechanistically, this was further associated with increased p53 transcriptional activation of p21 and PUMA . In addition, ERK5 inhibition increased the response of HCT116 p53 +/+ cells to 5-FU, but failed to sensitize HCT116 p53 −/− cells to the cytotoxic effects of this chemotherapeutic agent, suggesting a p53-dependent axis mediating 5-FU sensitization. Finally, ERK5 inhibition using XMD8-92 was shown to increase the antitumor effects of 5-FU in a murine subcutaneous xenograft model, enhancing apoptosis while markedly reducing tumor growth. Collectively, our results suggest that ERK5-targeted inhibition provides a promising therapeutic approach to overcome resistance to 5-FU-based chemotherapy and improve colon cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
de la Cruz-Morcillo, M. A., Valero, M. L. L., Callejas-Valera, J. L., Arias-González, L., Melgar-Rojas, P., Galán-Moya, E. M., García-Gil, E., García-Cano, J., & Sánchez-Prieto, R. (2012) · Oncogene · doi:10.1038/onc.2011.321 · Cited by 117 · cited 2×
“Remarkably, the effects of p38MAPK and JNK in controlling 5-FU response have also been shown to be p53-dependent [46, 47].”
BackgroundRetracted5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332 · cited 1×
“The p53 tumor suppressor is a major determinant of the balance between cell cycle arrest and apoptosis following 5-FU exposure [15].”
BackgroundInfluentialCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044 · cited 2×
“The antitumor activity of 5-FU has been greatly attributed to its ability to induce both p53 accumulation and activity [17, 18], leading to the direct transcription of cell-cycle inhibitory genes, such as p21/WAF1, and to the upregulation of several pro-apoptotic targets, including PUMA [18, 30].”
Background
Cited by
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Vaz, A. R., Pinto, S., Ezequiel, C., Cunha, C., Carvalho, L. A., Moreira, R., & Brites, D. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00109 · Cited by 55
Zargar, P., Ghani, E., Mashayekhi, F., Ramezani, A., & Eftekhar, E. (2018) · Oncology Letters · doi:10.3892/ol.2018.8569 · Cited by 23
Metadata
- Authors
- Pereira, D. M., Simões, A. E. S., Gomes, S. E., Castro, R. E., Carvalho, T., Rodrigues, C. M. P., & Borralho, P. M.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-04-29
- Volume
- 7
- Issue
- 23
- Pages
- 34322-34340
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2342484974
- Cited by
- 58
- References
- 5
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.